InvestorsHub Logo
Followers 53
Posts 4314
Boards Moderated 0
Alias Born 02/28/2010

Re: None

Wednesday, 04/30/2014 4:20:02 PM

Wednesday, April 30, 2014 4:20:02 PM

Post# of 1569
This will move higher into Tuesday's earnings report and conference call.

The company has the potential of receiving $1 Billion plus royalties from Amgen and Astellas for two of the drugs in its pipeline.

The current market cap of $160M substantially undervalues the company. I wouldn't be surprised to see upgrades after Tuesday with BUY ratings and price targets in the double digits.

I expect the company will move BENEFIT-ALS into phase 3 trials.

GLTA

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYTK News